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Glial cell derived neurotrophic factor (GDNF) holds promises for treating neurodegenerative diseases such as Parkinson’s dis-
ease. Human neural stem cells (hNSCs) have proved to be a suitable cell delivery vehicle for the safe and efficient introduction 
of GDNF into the brain. In this study, we used hNSCs-infected with a lentivirus encoding GDNF and the hygromycin re-
sistance gene as such vehicles. A modified tetracycline operator 7 (tetO7) was inserted into a region upstream of the EF1- 
promoter to drive GDNF expression. After hygromycin selection, hNSCs were infected with a lentivirus encoding a 
KRAB-tetracycline repressor fusion protein (TTS). TTS bound to tetO7 and suppressed the expression of GDNF in hNSCs. 
Upon administration of doxycycline (Dox) the TTS-tetO7 complex separated and the expression of GDNF resumed. The 
hNSCs infected with GDNF expressed the neural stem cell specific markers, nestin and sox2, and exhibited no significant 
change in proliferation rate. However, the rate of apoptosis in hNSCs expressing GDNF was lower compared with normal 
NSCs in response to actinomycin treatment. Furthermore, a higher percentage of Tuj-1 positive cells were obtained from 
GDNF-producing NSCs under conditions that induced differentiation compared to control NSCs. The inducible expression of 
GDNF in hNSCs may provide a system for the controllable delivery of GDNF in patients with neurodegenerative diseases. 
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Glial cell line-derived neurotrophic factor (GDNF) is a po-
tent and specific neurotrophic factor for dopaminergic neu-
rons [1]. Expression of GDNF in the striatum has been 
shown to prevent neurodegeneration and promote sprouting 
of nigral dopaminergic neurons in animal models and clini-
cal studies of Parkinson’s disease (PD) [2,3]. However, at-
tempts to apply GDNF clinically have so far been disap-
pointing because of its poor penetration across the blood-    
brain-barrier. Of several GDNF delivery methods, cell-     
based delivery systems provide a promising approach for 
treating PD. Human neural stem cells exhibit the potential 
to differentiate into neurons, astrocytes and oligodendro-
cytes[4,5], and may therefore provide an additional benefits 
for repair and replacement [6]. Several ex-vivo gene therapy 
studies have shown that GDNF-modified hNSCs could sur-
vive, migrate, secrete GDNF and differentiate into various 
cell types at the transplantation site in animal models of PD 
and amyotrophic lateral sclerosis (ALS) [7–9]. These stud-
ies suggest that GDNF-expressing hNSCs can provide a 
potential therapeutic strategy for treating neurodegenerative 
diseases. 
Although GDNF has the potential to improve the surviv-
al of dopaminergic neurons, continuous expression of 
GDNF leads to side effects such as aberrant axonal sprout-
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ing and down-regulation of tyrosine hydroxylase [10]. 
Therefore, it is necessary to control the level of GDNF pro-
duction at the site of cell transplantation in the brain. Trans-
planted cells modified with the GDNF gene are the ideal 
choice for controlling GDNF protein expression in the brain. 
To regulate foreign gene expression, the tetracycline-on 
(tet-on) [11] and tetracycline-off (tet-off) [12] operator sys-
tems have been developed. In the tet-off system, the con-
tinued presence of doxycycline (Dox) is required to sup-
press the expression of the gene of interest and therefore is 
not ideal where over-dosing of GDNF is a concern. However, 
one disadvantage of the “tet-on” system is the leakage 
problem, whereby expression of the target gene is not com-
pletely shut off in the absence of Dox [13]. To precisely and 
reversibly control the expression GDNF, we applied an im-
proved inducible lentiviral system comprising a modified 
tetracycline operator 7 (tetO7) and a tetracycline repressor 
fusion protein (TTS) modified by Betty Zhou [14]. In this 
system, one lentiviral vector expresses TTS and RFP, and 
the second vector expresses GDNF (or GFP) and the hy-
gromycin B resistance gene. When cells are co-infected 
with these two vectors, TTS can bind to tetO7 and suppress 
GDNF (or GFP) expression. Dox administration releases 
TTS from tetO7 to reversibly induce GDNF (or GFP) ex-
pression. This system can tightly control the expression of a 
target gene and was thus adopted in the present study. In 
this study, we investigated whether GDNF expression could 
be precisely and reversibly controlled in hNSCs infected 
with two inducible lentiviral vectors. 
1  Materials and methods 
1.1  Culture of human fetal neural stem cells 
Neural stem cells were prepared from the forebrain cortex 
of aborted embryos (16 weeks post conception). Briefly, 
fetal tissues were treated with 0.05% trypsin-EDTA (Invi-
trogen, Carlsbad, CA, USA) for 15 minutes at 37°C, fol-
lowing which trypsin inhibitor (Sigma-Aldrich, St. Louis, 
MO, USA) was added to terminate the enzymatic reaction. 
DNase (Sigma-Aldrich) was added to eliminate DNA re-
leased from the tissues. Single cell suspensions were har-
vested and filtered through 400-μm meshes to eliminate cell 
clusters. The single cell suspensions were plated onto cell 
culture dishes at a density of 2×105 cells mL1. The neuro-
spheres that formed after 5–7 days in culture were propa-
gated in growth medium containing DMEM-F12 (Invitro-
gen), N2 (Invitrogen), 20 ng mL1 EGF (R&D systems, 
Minneapolis, MN USA), 20 ng mL1 bFGF (R&D) and 1% 
BSA (Invitrogen). Half of the medium was changed every 
three days. For neuronal differentiation, the hNSCs were 
plated onto poly-D-lysine/laminin coated plates in differen-
tiation medium comprising DMEM-F12, N2, B27 and 1% 
BSA for two weeks. 
1.2  Lentiviral production and infection 
The lentiviral vector was constructed on the basis of a pre-
viously published vector, DUET101 [14]. We replaced the 
GFP sequence with the GDNF sequence. A tetO7 operator 
was also inserted upstream of the EF-1 promoter. Lentivi-
ral vectors encoding TTS and red fluorescent protein (RFP) 
were also constructed. The lentiviruses were produced by 
transient transfection. 293T cells were plated at 6×106 cells 
per 100 cm poly-D-lysine(Sigma-Aldrich) coated dish and 
incubated overnight. Three lentiviral vector plasmids (6 g 
of DUET101-GDNF, DUET101-GFP or TTS, 2 g of 
PMD.G, and 8 μg CMV8.91) were mixed with Lipofec-
tamine 2000 (Invitrogen) according to the manufacturer’s 
instructions and added to the 293T cells. After incubating 
for 8 hours, the medium was replaced with fresh medium 
comprising DMEM/F12 (Invitrogen) and ITS supplement 
(Invitrogen). After 48 h, the viral supernatants were col-
lected and concentrated by ultra-centrifugation. Viral titers 
were determined before hNSC infection. 293T cells were 
plated at a density of 1×105 cells per well in six-well plates 
and cultured overnight. Concentrated DUET101-GFP/TTS 
viral supernatants and polybrene (8 g mL1 Sigma) were 
added to the prepared 293T cells. 48 h later, the percentages 
of GFP and RFP positive cells were counted by FACS. Vi-
ral titers were calculated as transfection units (TU). If 10% 
of the cells were GFP positive following infection with 0.02 
mL of viral supernatant, then the viral titer is: 10%×target 
cell number (2×105 for 293T cells)/0.02 mL=1×106 TU 
mL1, assuming that the 293T cells doubled when infected. 
Prior to infecting the hNSCs, neurospheres were dissoci-
ated into single cells with accutase and seeded at a density 
of 2×105 cells cm2 in six-well plates. After incubating for 
72 h, concentrated viral supernatants for DUET101-GDNF 
or DUET101-GFP (control) were added to the NSC media 
together with 4 g mL1 polybrene. The multiplicity of in-
fection (MOI) was determined as the ratio of transfection 
units to cell number. Twenty-four hours later, the infection 
medium was aspirated and replaced with fresh NSC medi-
um. After expanding the infected hNSCs for two passages, 
100 g mL1 hygromycin was added to enrich the success-
fully infected cells. For regulation of GDNF expression, the 
selected hNSCs were infected with lentiviruses encoding 
TTS and RFP. The expression level of GDNF in hNSCs 
co-infected with DUET101-GDNF and TTS viral superna-
tants was determined by ELISA. 
1.3  ELISA 
Equal numbers of hNSCs infected with DUET101-GDNF 
were seeded at an appropriate density and infected with 
different viral MOIs, following which the medium was col-
lected 24 and 48 h later for ELISA assay. To determine 
whether the hNSCs secreted GDNF continuously and stably, 
the medium was collected at different time points (days 3, 7, 
14 and 21) and analyzed by ELISA. To determine whether 
34 Wang S Y, et al.   Sci China Life Sci   January (2013) Vol.56 No.1 
GDNF secretion by hNSCs could be regulated or controlled, 
the medium from the hNSCs was collected on days 1, 3 and 5 
after introducing the TTS virus. Then, different doses of Dox 
(2, 5, 10, 20, 50 ng mL1) were added and the medium was 
collected on days 1, 3, 5, 7 and 9 after Dox administration. 
The concentration of GDNF in the medium was determined 
using an ELISA kit (Promega Corporation, Madison, Wis-
consin, USA) according to the manufacturer’s instructions. 
1.4  Real-time PCR 
Total RNA was purified from hNSCs with TRIzol regent 
(Invitrogen) and treated with RNase-free DNase (Promega) 
to remove genomic DNA contamination. Two micrograms 
of RNA were used in a reverse transcription reaction with 
random primers (Invitrogen) and Superscript II reverse 
transcriptase kit (Invitrogen) according to the manufacturer’s 
protocol. For quantification of GDNF mRNA expression, 
human 18s RNA was used as the internal reference. Re-
al-time PCR was performed using the SYBR Green Premix 
Taq kit (Takara Biotechnology Co., Ltd, Dalian, China). 
Relative mRNA levels were quantified by the comparative 
Ct method. Primer sequences are listed in Table 1. 
1.5  Immunohistochemistry 
Differentiated hNSCs were fixed with PBS containing 4% 
paraformaldehyde for 10 min at room temperature. After 
washing with PBS, the cells were treated with PBS con-
taining 3% normal donkey serum (Jackson Immuno-   
Research Laboratories, Inc., Baltimore, USA) and 0.1% 
Triton X-100 for 60 min at room temperature. Primary an-
tibodies for nestin (1:400, Merck Millipore Headquarters, 
Billerica, USA), Tuj-1 (1:200, Millipore) and GFAP 
(1:200, Millipore) were added and incubated overnight at 
4°C. The secondary antibodies used were cyanine 3 
(Cy3)-conjugated donkey anti-mouse IgG (1:500, Jackson) 
and cyanine 2 (Cy2)-conjugated donkey anti-mouse IgGs. 
Nuclei were stained with DAPI. 
1.6  Apoptosis assays 
Normal hNSCs and LV-GDNF NSCs were exposed to ac-
tinomycin-D (1 mol L1) for 12 h. Apoptosis was evaluat-
ed as the percentage of annexin V-positive cells using an 
apoptosis kit (Invitrogen) according to the manufacturer’s 
instructions. 
2  Results 
2.1  The expression level of GDNF in hNSCs infected 
with DUET101-GDNF virus increased significantly in a 
manner proportional to the MOI value 
We constructed lentiviral vectors encoding GDNF under the 
control of the EF-1 promoter and the tet-O7 operator 
(Figure 1A). The modified hNSCs were resistant to hygro-
mycin and thus could be enriched. We first determined the 
infection efficiency of DUET101-GFP as a control for 
DUET101-GDNF viral infection. The average titer of con-
centrated DUET101-GFP viral supernatants was about 
5×107 TU mL1. hNSCs infected with DUET101-GFP virus 
at different MOI values (0, 0.5, 1, 2.5, 5, 10) were analyzed 
by FACS. The results indicated that 44.5% of hNSCs were 
GFP positive when MOI=1 (Figure 1E). The percentage of 
GFP positive cells increased gradually with the MOI value. 
To purify successfully infected cells, hygromycin was added 
to the culture medium. After hygromycin selection, the per-
centage of GFP-positive cells increased to 99.5% (Figure 
1F). The same selection procedure was performed after 
hNSCs were infected with DUET101-GDNF. We deter-
mined the GDNF expression level in the supernatants of 
purified hNSC infected with DUET101-GDNF at different 
MOI values (0, 0.5, 1, 2.5, 5, 10) by ELISA. The results 
indicated that the GDNF expression level in hNSCs infected 
with DUET101-GDNF increased significantly compared 
with control cells (MOI=0). Furthermore, the GDNF ex-
pression level increased proportional to the MOI value 
(Figure 2A). At the same time, the GNDF mRNA levels in 
hNSCs infected with DUET101 GDNF at different MOI 
values (0, 0.5, 1, 2.5, 5, 10) were also analyzed by real-time 
PCR. The results indicated that the GDNF mRNA levels in 
infected hNSCs increased proportional to the MOI value 
(Figure 2B). We further determined the GDNF expression 
level at different time points (days 3, 7, 14, 21 40) after in-
fection. The results showed that infected hNSCs could se-
crete GDNF continuously and stably. The GDNF expression 
level in infected hNSCs was maintained at a higher level 
than in control cells (Figure 2C). These results indicated 
that GDNF secretion was significantly improved in hNSCs 
infected with DUET101-GDNF. Furthermore, the GDNF 
expression level in hNSCs increased with the MOI value. 
The hygromycin-selected hNSCs over-expressed GDNF 
continuously and stably. These data indicate that GDNF 
expression can be controlled in human fetal neural stem 
cells. 
2.2  Tight regulation of GNDF expression in hNSCs 
On the basis that purified hNSCs over-expressing GDNF 
could be cultured and propagated, the TTS vector was in-
troduced to regulate and control GDNF expression. The 
TTS vector encodes a fusion protein containing a tetracy-
cline repressor (tetR) domain and RFP (Figure 1B). The 
hNSCs successfully infected with TTS were RFP positive 
(Figure 3A and B). When these neurospheres were dissoci-
ated into single cells, FACS analysis indicated that about 
96.65% of the cells were RFP positive (Figure 3C and D). 
These results indicated that DUET101-GDNF and TTS 
were both expressed in hNSCs. Therefore, the tetR fusion  
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Figure 1  Schematic representation of the GDNF inducible lentiviral vectors and the infection efficiency assay. A, The DUET101-GDNF lentiviral vector 
expresses the GDNF and hygromycin resistance genes driven by EF1-a and PGK, respectively. A modified tetracycline operator 7 (tetO7) was inserted up-
stream of EF1-. B, The TTS vector encodes the TTS protein (a fusion protein of KRAB and tetracycline repressor) and red fluorescent protein (RFP). C, 
Bright field view of neurospheres infected with DUET101-GFP. D, Fluorescence micrograph showing GFP-positive neurospheres. Scale bar, 50 m. E, Prior 
to hygromycin selection, about 44.5% of cells were GFP-positive. F, Following hygromycin selection, about 99.5% of cells were GFP-positive. 
 
protein can bind to the tetracycline operator, tetO7, and 
suppress gene expression in the absence of Dox. We col-
lected the medium from the hNSCs on days 1, 3 and 5 after 
infection with the TTS virus. The concentration of secreted 
GDNF was analyzed by ELISA. The results showed that 
extracellular GDNF secretion declined to background levels 
after introduction of the TTS vector (Figure 3F). The de-
creased GDNF secretion indicated that GDNF expression 
could be inhibited by introducing the TTS vector. Following 
Dox treatment, GDNF expression was restored by release of 
TTS from tetO7. Following this confirmation that GDNF 
expression in hNSCs could be suppressed with TTS, differ-
ent doses of Dox (2, 5, 10, 20 and 50 ng mL1) were added 
and the medium was collected for GDNF ELISA on days 1, 
3, 5, 7 and 9. The results indicated that the concentration of 
secreted GDNF increased gradually up to day 7 after addition 
of Dox (5 ng mL1) (Figure 3G). In hNSCs co-infected with 
DUET101-GFP and TTS viruses, a gradual transition from 
RFP to GFP expression was seen (Figure 3E). Upon removal 
of Dox from the medium, the expression of GDNF was 
rapidly shut off (data not shown). The up- and down-regula-       
tion of GDNF can be repeated for several cycles by the addi-
tion and removal of Dox. The response to Dox treatment 
was quite sensitive and a dose of Dox as low as 5 ng mL1 
was sufficient to drive the expression of GDNF. These re-
sults suggest that GDNF can be tightly and efficiently con- 
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Figure 2  The GDNF expression level in hNSCs infected with DUET101-GDNF virus increased significantly and was directly proportional to MOI value. 
A, ELISA analysis of the concentration of secreted GDNF at different MOI values. Compared with control, the concentration of GDNF secreted by hNSCs 
infected with DUET101-GDNF increased significantly and was proportional to the MOI value (ANOVA analysis; *, P<0.01). B, Real-time PCR analysis of 
GDNF mRNA levels at the indicated MOI values. The GDNF mRNA expression level in hNSCs infected with DUET101-GDNF was significantly elevated 
and was proportional to the MOI value after normalization to an internal reference (human 18s ribosome RNA) (ANOVA analysis; *, P<0.01). C, ELISA 
analysis of GDNF expression for 40 d after infection of hNSCs with different MOIs of GDNF lentivirus. DUET101-GDNF-infected hNSCs over-expressed 
GDNF stably and continuously, and the relationship between GDNF secretion and MOI was stable. 
Table 1  Real-time PCR primer list 
Primer name Primer sequence 
GDNF forward ACTGACTTGGGTCTGGGCTATG 
GDNF reverse TTTGTCACTCACCAGCCTTCTATTT 
Human 18S forward ACTCAACACGGGAAACCTCA 
Human 18S reverse AACCAGACAAATCGCTCCAC 
 
trolled in our system. 
2.3  Decreased apoptosis and increased neuronal dif-
ferentiation in hNSCs infected with DUET101-GDNF 
To investigate whether GDNF over-expression would affect 
the characteristics of hNSCs, we examined antigen expres-
sion, proliferation, apoptosis and differentiation in hNSCs 
infected with DUET101-GDNF and TTS. Immunohisto-
chemistry demonstrated that hNSCs infected with 
DUET101-GDNF expressed the neural stem cell specific 
markers, nestin and sox2 (data not shown). When actino-
mycin-D was added to induce apoptosis, hNSCs infected 
with DUET101-GDNF showed a lower percentage of an-
nexin V-positive cells compared with normal hNSCs (Fig-
ure 4A). After natural differentiation, the percentage of early 
neurons (Tuj-1 positive) and astrocytes (GFAP positive) 
was analyzed. The results showed that the percentage of 
Tuj-1 positive cells that differentiated from hNSCs infected 
with DUET101-GDNF increased significantly (Figure 4B). 
Comparison of the biological characteristics of infected and 
control cells indicated that antigen expression and prolifera-
tion were not changed by GDNF over-expression. Further-
more, apoptosis was reduced and neuronal differentiation 
was increased significantly in hNSCs over-expressing 
GDNF. These cellular characteristics may be considered 
desirable for the application of hNSCs to cell therapy for 
neurodegenerative disease. 
3  Discussion 
Certain potential adverse events, including extensive aber-
rant fiber sprouting downstream of striatal targets and lack 
of functional recovery, have been observed in studies using 
regular lentivirus-mediated GDNF delivery [10]. Although 
the mechanisms underlying these effects remain elusive, 
these results indicate that vector-mediated GDNF delivery 
may have to be maintained within a defined dose range to 
avoid over-dosing effects [15]. In this study, we demon-
strated that an inducible lentiviral expression system can 
efficiently mediate the tight regulation of GDNF expression 
in human neural stem cells. The correlation between GDNF 
secretion and lentivirus MOI values provides the first layer 
of control over the desired expression of GDNF, i.e., by  
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Figure 3  Tight regulation of GDNF secretion in hNSCs using an inducible lentiviral vector system. A, After infection with the TTS vector, neurospheres 
formed by DUET101-GDNF hNSCs were RFP positive under fluorescence microscopy. B, Bright field view of the neurospheres formed by LV-GDNF 
hNSCs shown in A. Scale bar, 50 µm. C, More than 90% of cells were RFP positive when the infected neurospheres were dissociated into single cells. D, 
Bright field view of the single cells dissociated from infected neurospheres shown in C. Scale bar, 100 µm. E, After Dox administration, the control group 
hNSCs co-infected with DUET101-GFP and TTS began to change from RFP to GFP positive. F, ELISA analysis of the concentration of GDNF secreted by 
DUET101-GDNF hNSCs infected with TTS (MOI=5). The concentration of GDNF secreted by DUET101-GNDF hNSCs decreased to the control level 
within 48 h after introduction of TTS. G, ELISA analysis of the concentration of GDNF secreted by hNSCs co-infected with DUET101-GDNF and TTS 
after Dox (5 ng mL1) administration. The concentration of GDNF secreted by hNSCs co-infected with DUET101-GDNF and TTS increased gradually and 
returned to the unsuppressed level after treatment with Dox for 5–7 d. 
adjusting the number of virus particles for infection of 
NSCs. The reversible Dox responsiveness suggests a con-
venient means to shut off GDNF expression when produc-
tion of GDNF is no longer needed or has caused a side ef-
fect. The functionality of our inducible systems offers an 
opportunity for maintaining GDNF gene delivery within a 
defined dose range. We used KRAB-mediated repression 
and the tetracycline repressor, tetO7, in our inducible sys-
tems. It has been demonstrated that KRAB-mediated re-
pression can eliminate the leaky, non-specific expression 
that frequently affects transactivation-based conditional 
systems [1618]. We demonstrated that GDNF expression 
in our system could reach a plateau level within three days, 
suggesting a fast response to Dox. If the Dox concentration 
was maintained at a certain level, GDNF secretion also re-
mained stable. Upon removal of Dox, GDNF expression  
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Figure 4  Apoptosis was reduced and neuronal differentiation was increased in hNSCs over-expressing GDNF. A, FACS analysis of annexin V-positive 
cells after treatment with actinomycin-D (1 mol L1). Annexin V-positive cells infected with DUET101-GDNF decreased by 13.2% compared with normal, 
non-infected hNSCs. *, P<0.01. B, Analysis of the percentage of Tuj-1 positive cells after natural differentiation of control and DUET101-GDNF hNSCs. 
The percentage of Tuj-1 positive LV-GDNF hNSCs increased significantly at different MOI values compared to normal hNSCs. *, P<0.05. 
 
tapered off within 5–7 d. In the TTS-suppressed state, the 
GDNF protein levels did not show a significant difference 
compared with the control group (non-infected NSCs), 
suggesting that the leakage problem, which is a key concern 
for viral vector-based clinical approaches [19], does not 
exist in our system. 
Because lentiviral vectors are retrovirus-based, the se-
quence of the vector itself and the foreign gene would inte-
grate into the genomic DNA of the host cells. Therefore, the 
use of lentiviral vectors as gene therapy vehicles is contro-
versial. We demonstrated that hNSCs did not show obvious 
changes in proliferation and antigen expression, indicating 
that the current system is relatively safe. Prior studies ap-
plying regular lentivirus-based cell therapy in animal mod-
els did not report any detectable cellular pathology or im-
mune reactions [20], further suggesting that lentiviral vec-
tors may be safe vehicles for GDNF delivery. Furthermore, 
compared with the control group, hNSCs infected with 
DUET101-GDNF showed a lower rate of apoptosis when 
treated with actinomycin and a higher percentage of Tuj-1 
positive cells when cultured under conditions that induced 
differentiation. These results suggest that GDNF may not 
only exert a beneficial effect on injured neurons in the host 
but also promote the survival and neuronal differentiation of 
grafted hNSCs. 
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